Archives
-
HDAC6 Tubulin Lactylation and Microtubule Dynamics
2026-09-11
The reference study identifies α-tubulin K40 lactylation as a metabolism-sensitive post-translational modification that increases microtubule dynamics in neurons. It further establishes HDAC6 as a principal lactylation writer, linking intracellular lactate to cytoskeletal remodeling, neurite outgrowth, and branching.
-
Eltanexor (KPT-8602) Workflow for XPO1 Studies
2026-09-10
Build a practical Eltanexor workflow that connects XPO1 inhibition with nuclear-retention, viability, Wnt/β-catenin, and COX-2 readouts. The approach spans hematologic models and colorectal cancer organoids while separating published evidence from assay-development recommendations.
-
HLY78: Wnt/β-Catenin Pathway Modulator Guide
2026-09-10
HLY78 provides ligand-dependent potentiation of Wnt/β-catenin signaling through the Axin-LRP6 interface, making it useful for mechanism-focused cell, zebrafish, and developmental assays. This guide translates that mechanism into practical workflows while distinguishing established evidence from exploratory fibrosis applications.
-
AZD1480 and the Tumor-Protective JAK2/STAT3 Axis
2026-09-09
Tumor-directed immune activation can produce compensatory survival signaling inside cancer cells. This thought-leadership analysis positions AZD1480 as a mechanistic JAK2 inhibitor for testing IL-6–JAK2/STAT3 adaptation, refining biomarker strategy, and designing translational combination studies.
-
TAI-1 Hec1 Inhibitor for Mitotic Cancer Research
2026-09-09
TAI-1 combines potent Hec1-Nek2 pathway disruption with practical applications in mitotic imaging, apoptosis profiling, genotype-stratified screening, and chemotherapy combinations. This guide translates the product evidence and a recent transcription–replication conflict study into actionable workflows for cancer cell and translational research.
-
Roscovitine and the Next Wave of Tumor Translation
2026-09-08
Roscovitine (Seliciclib, CYC202) offers a mechanistically defined way to interrogate CDK-dependent cell-cycle control alongside emerging radiotherapy and immunotherapy strategies. This thought-leadership guide separates established evidence from translational hypotheses and outlines rigorous workflows for cancer biology research.
-
How Simvastatin Reshapes Phospholipid Bilayers
2026-09-08
The reference study uses all-atom molecular dynamics simulations to compare the membrane behavior of simvastatin’s neutral lactone and active dihydroxyheptanoate forms. Its central contribution is showing that chemical state and membrane composition jointly determine drug localization, hydrogen bonding, lipid order, and bilayer fluidity—variables relevant to interpreting both pharmacology and statin-associated membrane effects.
-
Sulforaphane, Oxidative Stress, and NLRP3 in Colitis
2026-09-07
A 2024 study in a dextran sodium sulfate-induced mouse model shows that Sulforaphane reduces colonic oxidative stress and suppresses NLRP3 inflammasome signaling. The work connects reactive oxygen species reduction with lower NLRP3, ASC, caspase-1, IL-1β, and IL-18 responses, providing a mechanistic framework for studying inflammatory bowel disease.
-
Trichostatin A: From HDAC Biology to Translation
2026-09-07
Trichostatin A (TSA) is more than a benchmark HDAC inhibitor: it is a controllable perturbation tool for connecting histone acetylation with cell-state transitions, cancer phenotypes, oxidative stress, and tissue integration. This thought-leadership guide translates mechanistic evidence into practical design principles for oncology, differentiation, and regenerative research.
-
BQCA: Reframing M1 Signaling for Translation
2026-09-05
Benzyl Quinolone Carboxylic Acid (BQCA) is more than a selective M1 probe. Its ability to potentiate acetylcholine receptor signaling, penetrate the brain, and reveal GRK-dependent changes in receptor-transducer interactions makes it a strategic tool for translational neuropharmacology. This article connects BQCA pharmacology with experimental design, Alzheimer’s disease research, cognitive function modulation, and the interpretation of biased M1 signaling.
-
EZ Cap Cy5 Firefly Luciferase mRNA Workflows
2026-09-04
Pair Cy5 fluorescence with Firefly luciferase to separate mRNA uptake, intracellular trafficking, and productive translation in one workflow. This guide shows how to optimize delivery systems, interpret dual-modality data, and troubleshoot common assay failures using a 5-moUTP modified mRNA reporter.
-
Colorectal Metastasis and Therapeutic Heterogeneity
2026-09-04
Cho and colleagues used matched patient-derived xenograft models and multi-omic profiling to show that colorectal cancer metastases can diverge through coordinated genomic, transcriptomic, and epigenomic evolution. Their results connect lesion-specific subclonal changes with heterogeneous in vivo drug responses, emphasizing why treatment biomarkers must account for metastatic evolution rather than relying only on the primary tumor.
-
Reparixin: CXCR1/2 Assays for IL-8 Biology
2026-09-03
Reparixin provides a practical pharmacological test of CXCL8–CXCR1/2 signaling in neutrophil migration, inflammatory injury, and emerging tumor–microbe models. This guide connects assay setup, MRSA extracellular-vesicle biology, formulation control, and troubleshooting without treating receptor blockade as proof of a complete cancer mechanism.
-
CTCF Maintains Centromere Function in Mitosis
2026-09-03
The reference study uses rapid, inducible CTCF degradation to show that CTCF preserves centromere mechanics, metaphase chromosome organization, mitotic fidelity, and post-mitotic nuclear shape. Its results distinguish CTCF loss from simple CENP-E failure and support a centromere-maintenance role linked to cohesin-dependent chromosome architecture.
-
HFPO-DA, CK2, and Ischemic Stroke Injury
2026-09-02
A 2026 rat study identifies HFPO-DA, or GenX, as an environmental factor that worsens ischemia–reperfusion brain injury and implicates the CSNK2A1/GSK3B/NF-κB axis in this effect. By combining exposure modeling, molecular docking, CETSA, CSNK2A1 knockdown, and pharmacological rescue with CX-4945, the work connects a PFAS substitute to microglia-associated neuroinflammation.